KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Amortization - Intangibles (2017 - 2024)

Historic Amortization - Intangibles for BeOne Medicines (ONC) over the last 8 years, with Q2 2024 value amounting to $1.2 million.

  • BeOne Medicines' Amortization - Intangibles rose 1449.42% to $1.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.6 million, marking a year-over-year increase of 9105.79%. This contributed to the annual value of $7.2 million for FY2023, which is 8206.74% up from last year.
  • As of Q2 2024, BeOne Medicines' Amortization - Intangibles stood at $1.2 million, which was up 1449.42% from $1.2 million recorded in Q1 2024.
  • BeOne Medicines' 5-year Amortization - Intangibles high stood at $3.0 million for Q4 2023, and its period low was $187000.0 during Q3 2020.
  • Over the past 5 years, BeOne Medicines' median Amortization - Intangibles value was $977500.0 (recorded in 2022), while the average stood at $896444.4.
  • As far as peak fluctuations go, BeOne Medicines' Amortization - Intangibles crashed by 4350.45% in 2020, and later surged by 44255.32% in 2022.
  • BeOne Medicines' Amortization - Intangibles (Quarter) stood at $188000.0 in 2020, then surged by 335.64% to $819000.0 in 2021, then increased by 18.32% to $969000.0 in 2022, then soared by 205.16% to $3.0 million in 2023, then crashed by 60.2% to $1.2 million in 2024.
  • Its Amortization - Intangibles stands at $1.2 million for Q2 2024, versus $1.2 million for Q1 2024 and $3.0 million for Q4 2023.